Credit Suisse Ag Forma Therapeutics Holdings, Inc. Transaction History

Credit Suisse Ag

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 10, 2022	BUY	$7.12 - $20.24 $694,776 - $1.98 Million	97,581 Added 759.44%	110,430 $2.2 Million
Q2 2022 Aug 12, 2022	BUY	$5.1 - $10.0 $714 - $1,400	140 Added 1.1%	12,849 $89,000
Q1 2022 May 16, 2022	SELL	$8.34 - $14.69 $12,426 - $21,888	-1,490 Reduced 10.49%	12,709 $118,000
Q4 2021 Feb 14, 2022	BUY	$13.6 - $24.89 $57,895 - $105,956	4,257 Added 42.82%	14,199 $201,000
Q3 2021 Nov 12, 2021	BUY	$21.22 - $25.7 $16,954 - $20,534	799 Added 8.74%	9,942 $230,000
Q2 2021 Aug 16, 2021	SELL	$22.86 - $30.95 $67,116 - $90,869	-2,936 Reduced 24.31%	9,143 $227,000
Q1 2021 May 14, 2021	SELL	$24.58 - $42.82 $481,595 - $838,972	-19,593 Reduced 61.86%	12,079 $339,000
Q4 2020 Feb 12, 2021	BUY	$34.9 - $51.08 $1.11 Million - $1.62 Million	31,672 New	31,672 $1.11 Million

26.5K

Ticker FMTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 47,860,400
Market Cap $958M
Description
Forma Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on development and commercialization of novel therapeutics for treatment of rare hematologic diseases and cancers. Its core product candidates for development include FT-4202, which is Phase 1 trial for the treatment of sickle cell disease and other hemoglobin...

Get notified when there are updates to the investment portfolio of Credit Suisse Ag, based on Form 13F filings with the SEC.

Stay updated on Credit Suisse Ag with notifications on news.